Industry Update: The latest developments in therapeutic delivery

    loading  Checking for direct PDF access through Ovid

Abstract

The present Industry Update covers the period 6 September to 5 October 2011, with information sourced from company press releases, media newswires, regulatory agencies and relevant patent offices. The previously announced merger between Alkermes and Elan Drug Technologies has finally taken place following shareholder approval on 8 September. Notable regulatory approvals include Gilenya® as a once-daily treatment in Japan for the prevention of relapse and delay of progression of physical disability in adults with multiple sclerosis, while the topline BOLERO-2 clinical trial results presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden showed Afinitor® significantly enhances benefit from exemestane hormonal therapy, representing an important advance for women with postmenopausal ER+ breast cancer.

Related Topics

    loading  Loading Related Articles